{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:58:19Z","timestamp":1785761899875,"version":"3.56.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:00:00Z","timestamp":1757203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.gore.2025.101950","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:05:27Z","timestamp":1757376327000},"page":"101950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Adverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4470-8019","authenticated-orcid":false,"given":"Yasmin","family":"Abozenah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Greenman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Daigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Paul","family":"Mikhaiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"DiCapua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Azodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Altwerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.gore.2025.101950_b0005","first-page":"2274","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.gore.2025.101950_b0010","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.gore.2025.101950_b0015","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1016\/S0735-1097(23)03997-9","article-title":"Immunosuppression-resistant immune checkpoint inhibitor-induced myocarditis treated successfully with addition of tofacitinib","volume":"81","author":"Kwan","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"issue":"16","key":"10.1016\/j.gore.2025.101950_b0020","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3390\/diagnostics14161794","article-title":"Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review","volume":"14","author":"Lipe","year":"2024","journal-title":"Diagnostics"},{"issue":"33","key":"10.1016\/j.gore.2025.101950_b0025","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (GOG-0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.gore.2025.101950_b0030","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gore.2025.101950_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin\u2013paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","author":"Powell","year":"2024","journal-title":"Ann. Oncol."},{"issue":"17","key":"10.1016\/j.gore.2025.101950_b0040","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Schneider","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.gore.2025.101950_b0045","first-page":"452","article-title":"Myocarditis, myositis, and myasthenia gravis overlap syndrome induced by immune checkpoint inhibitors","volume":"27","author":"Suzuki","year":"2022","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.gore.2025.101950_b0050","first-page":"566","article-title":"Immune-related adverse events from checkpoint blockade therapy in cancer: mechanisms and management","volume":"18","author":"Vijayan","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925001754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925001754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:09:50Z","timestamp":1761185390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578925001754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":10,"alternative-id":["S2352578925001754"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2025.101950","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2025.101950","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101950"}}